Agraz AV, Rafiq M, Guru B, Madan MN, Anturlikar SD, Azeemuddin MM, Manjula SN. Evaluation of immunomodulatory activity of Immusante® in zebrafish. J Appl Biol Biotechnol, 2021; 9(3):7-2. |
|
Elgawish MS, Soltan MK, Sebaiy MM. An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and irbesartan in rat plasma: insight into pharmacokinetic and drug-drug interaction studies. J Pharm Biomed Anal, 2019; 174:226-34.
https://doi.org/10.1016/j.jpba.2019.05.069 | |
|
Firashathulla S, Inamdar MN, Rafiq M, Viswanatha GL, Sharath Kumar LM, Babu UV, Ramakrishnan S, Paramesh R. IM-133N-a useful herbal combination for eradicating disease-triggering pathogens in mice via immunotherapeutic mechanisms. J Pharmacopuncture, 2016; 19(1):21-7. doi: 10.3831/KPI.2016.19.003.
https://doi.org/10.3831/KPI.2016.19.003 | |
|
International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek- Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov, 2010; 9(3):215-36; doi: 10.1038/nrd3028.
https://doi.org/10.1038/nrd3028 | |
|
Jayanthi CR, Avinash HR, Sridhar S, Akhila K, Kumawat R. A randomized control study to evaluate the role of herbal immunomodulators in boosting the immunity and overall health of healthcare workers in COVID-19 wards: an exploratory, feedback clinical study. Asian J Pharm Clin Res, 2021; 14:138-42.
https://doi.org/10.22159/ajpcr.2021.v14i8.42035 | |
|
Le Blaye O. The EMA guideline on bioanalytical method validation. EMA, London, UK, 2011. | |
|
Gangwar V, Garg A, Lomore K, Korla K, Bhat SS, Rao RP, Rafiq M, Kumawath R, Uddagiri BV, Kareenhalli VV. Immunomodulatory effects of a concoction of natural bioactive compounds-mechanistic insights. Biomedicines. 2021; 9(11):1522.
https://doi.org/10.3390/biomedicines9111522 | |
|
Giacomini KM, Huang SM. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther, 2013; 94(1):3-9. doi: 10.1038/clpt.2013.86.
https://doi.org/10.1038/clpt.2013.86 | |
|
Grobler L, Durao S, Van Der Merwe S M, Wessels J, Naude C E. Nutritional supplements for people being treated for active tuberculosis: a technical summary. S Afr Med J, 2016; 108(1):16-8.
https://doi.org/10.7196/SAMJ.2017.v108i1.12839 | |
|
Long NP, Par S, Anh .H, Kim SJ, Kim HM, Yoon SJ, Lim J, & Kwon SW. Advances in liquid chromatography-mass spectrometry-based lipidomics: a look ahead. J Anal Test, 2020; 4:1-5.
https://doi.org/10.1007/s41664-020-00135-y | |
|
Marsot A, Ménard A, Dupouey J, Muziotti C, Guilhaumou R, Blin O. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. Br J Clin Pharmacol, 2017; 83(5):1039-47; doi: 10.1111/bcp.13178.
https://doi.org/10.1111/bcp.13178 | |
|
Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci, 2004; 96(3):293-300.
https://doi.org/10.1254/jphs.FP0040296 | |
|
Sachin BS, Monica P, Sharma SC, Satti NK, Tikoo MK, Tikoo AK. Pharmacokinetic interaction of some antitubercular drugs with caraway: implications in the enhancement of drug bioavailability. Hum Exp Toxicol, 2009; 28:175-84.
https://doi.org/10.1177/0960327108097431 | |
|
Tasduq SA, Kaiser P, Sharma SC, Johri RK. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study. Hepatol Res, 2007; 37(10):845-53. doi: 10.1111/j.1872-034X.2007.00129.x.
https://doi.org/10.1111/j.1872-034X.2007.00129.x | |
|
Unissa AN, Selvakumar N, Narayanan S. Characterization of isoniazid-resistant mutant (S315R) of catalase-peroxidase, KatG, from Mycobacterium tuberculosis. Int J Med Sci Technol, 2011; 4(3):13-22. | |
|
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology, 2002; 36(1):164-72. doi: 10.1053/ jhep.2002.34133.
https://doi.org/10.1053/jhep.2002.34133 | |
|
Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet, 1992; 22(1):47-65; doi: 10.2165/00003088- 199222010-00005. Zhang L, Zhao Y, Gao Y, Wu L, Gao R, Zhang Q, Wang Y, Wu C, Wu F, Gurcha SS, Veerapen N, Batt SM, Zhao W, Qin L, Yang X, Wang M, Zhu Y, Zhang B, Bi L, Zhang X, Yang H, Guddat LW, Xu W, Wang Q, Li J, Besra GS, Rao Z. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science, 2020; 368(6496):1211-9; doi: 10.1126/science.aba9102.
https://doi.org/10.1126/science.aba9102 | |
|
Zhang Y, Shi W, Zhang W, Mitchison D. Microbiol Spectr, 2014; 2(4):1-2.
https://doi.org/10.1128/microbiolspec.MGM2-0023-2013 | |